<DOC>
	<DOCNO>NCT00548834</DOCNO>
	<brief_summary>The purpose study confirm extend data previous study demonstrate efficacy ( term sign symptom ) safety monotherapy CDP870 administer SC every 4 week compare placebo patient active RA fail least one DMARD .</brief_summary>
	<brief_title>Efficacy Safety CDP870 Versus Placebo Treatment Signs Symptoms Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Signs Symptoms</mesh_term>
	<mesh_term>Certolizumab Pegol</mesh_term>
	<criteria>male/female , 1875 year old , inclusive diagnosis adultonset RA active disease receive methotrexate stable dose folic acid contraindication methotrexate antiTNF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>CDP870</keyword>
	<keyword>Certolizumab Pegol</keyword>
</DOC>